164 related articles for article (PubMed ID: 31036624)
1. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for
Spiliopoulou A; Colombo M; Plant D; Nair N; Cui J; Coenen MJ; Ikari K; Yamanaka H; Saevarsdottir S; Padyukov L; Bridges SL; Kimberly RP; Okada Y; van Riel PLC; Wolbink G; van der Horst-Bruinsma IE; de Vries N; Tak PP; Ohmura K; Canhão H; Guchelaar HJ; Huizinga TW; Criswell LA; Raychaudhuri S; Weinblatt ME; Wilson AG; Mariette X; Isaacs JD; Morgan AW; Pitzalis C; Barton A; McKeigue P
Ann Rheum Dis; 2019 Aug; 78(8):1055-1061. PubMed ID: 31036624
[TBL] [Abstract][Full Text] [Related]
2. Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.
Umićević Mirkov M; Janss L; Vermeulen SH; van de Laar MA; van Riel PL; Guchelaar HJ; Brunner HG; Albers CA; Coenen MJ
Ann Rheum Dis; 2015 Dec; 74(12):2183-7. PubMed ID: 25114059
[TBL] [Abstract][Full Text] [Related]
3. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts.
Sánchez-Maldonado JM; Cáliz R; López-Nevot MÁ; Cabrera-Serrano AJ; Moñiz-Díez A; Canhão H; Ter Horst R; Quartuccio L; Sorensen SB; Glintborg B; Hetland ML; Filipescu I; Pérez-Pampin E; Conesa-Zamora P; Swierkot J; den Broeder AA; De Vita S; Petersen ERB; Li Y; Ferrer MA; Escudero A; Netea MG; Coenen MJH; Andersen V; Fonseca JE; Jurado M; Bogunia-Kubik K; Collantes E; Sainz J
Front Immunol; 2021; 12():672255. PubMed ID: 34777329
[TBL] [Abstract][Full Text] [Related]
4. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
[TBL] [Abstract][Full Text] [Related]
5. Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis.
Luque-Tévar M; Perez-Sanchez C; Patiño-Trives AM; Barbarroja N; Arias de la Rosa I; Abalos-Aguilera MC; Marin-Sanz JA; Ruiz-Vilchez D; Ortega-Castro R; Font P; Lopez-Medina C; Romero-Gomez M; Rodriguez-Escalera C; Perez-Venegas J; Ruiz-Montesinos MD; Dominguez C; Romero-Barco C; Fernandez-Nebro A; Mena-Vazquez N; Marenco JL; Uceda-Montañez J; Toledo-Coello MD; Aguirre MA; Escudero-Contreras A; Collantes-Estevez E; Lopez-Pedrera C
Front Immunol; 2021; 12():631662. PubMed ID: 33833756
[No Abstract] [Full Text] [Related]
6. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
8. Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.
Nguyen MVC; Baillet A; Romand X; Trocmé C; Courtier A; Marotte H; Thomas T; Soubrier M; Miossec P; Tébib J; Grange L; Toussaint B; Lequerré T; Vittecoq O; Gaudin P
Joint Bone Spine; 2019 Mar; 86(2):195-201. PubMed ID: 29885551
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
[TBL] [Abstract][Full Text] [Related]
10. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
11. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry.
Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E
Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
[TBL] [Abstract][Full Text] [Related]
14. Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care.
Naniwa T; Iwagaitsu S; Kajiura M
Mod Rheumatol; 2020 Nov; 30(6):948-958. PubMed ID: 31814481
[No Abstract] [Full Text] [Related]
15. A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.
Jiang X; Askling J; Saevarsdottir S; Padyukov L; Alfredsson L; Viatte S; Frisell T
Arthritis Res Ther; 2016 Dec; 18(1):288. PubMed ID: 27912794
[TBL] [Abstract][Full Text] [Related]
16. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA
J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007
[TBL] [Abstract][Full Text] [Related]
17. CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients.
Boral B; Tuncer İ; Kibar F; Çetiner S; Badak SÖ; Salman E; Koç E; Erken E; Yaman A
Turk J Med Sci; 2023; 53(5):1075-1083. PubMed ID: 38813034
[TBL] [Abstract][Full Text] [Related]
18. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway.
Li G; Diogo D; Wu D; Spoonamore J; Dancik V; Franke L; Kurreeman F; Rossin EJ; Duclos G; Hartland C; Zhou X; Li K; Liu J; De Jager PL; Siminovitch KA; Zhernakova A; Raychaudhuri S; Bowes J; Eyre S; Padyukov L; Gregersen PK; Worthington J; ; Gupta N; Clemons PA; Stahl E; Tolliday N; Plenge RM
PLoS Genet; 2013 May; 9(5):e1003487. PubMed ID: 23696745
[TBL] [Abstract][Full Text] [Related]
19. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
[TBL] [Abstract][Full Text] [Related]
20. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Emery P; Gottenberg JE; Rubbert-Roth A; Sarzi-Puttini P; Choquette D; Taboada VM; Barile-Fabris L; Moots RJ; Ostor A; Andrianakos A; Gemmen E; Mpofu C; Chung C; Gylvin LH; Finckh A
Ann Rheum Dis; 2015 Jun; 74(6):979-84. PubMed ID: 24442884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
